Compare Johnson & Johnson (JNJ) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Li Auto Inc — how do they compare? Johnson & Johnson trades at $249.62 (market cap $598.96B), while Li Auto Inc trades at $12.28 (market cap $12.43B). The key difference: Johnson & Johnson is far larger — about 48.2× Li Auto Inc's market cap, and Johnson & Johnson pays a 2.15% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals.
| JNJ | LI | |
|---|---|---|
Market Cap | $598.96B | $12.43B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $30.84 |
52-Week Low | $164.36 | $11.74 |
Enterprise Value | $631.90B | $1.34B |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
LI Auto trades at $12.42, up 0.24% on the day, with a bearish technical signal and mixed earnings history. The company reported a net income margin of -1.66% for 2025, with revenue declining to $112.31B from $144.5B in 2024. Recent news highlights the launch of new SUV models like the Li L6, aiming to boost deliveries amid competitive pressures.
Outlook remains cautious with analyst consensus at Buy (43.75%) but near-term risks from intense EV competition and profitability challenges. The stock trades below the consensus price target of $14.80, offering potential upside if execution improves, but investors face headwinds from margin pressure and volatile cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
